Free Trial

BioLineRx (BLRX) News Today

$0.85
+0.04 (+4.41%)
(As of 12:27 PM ET)
BioLineRx logo with Medical background
BioLineRx Ltd. (NASDAQ:BLRX) Short Interest Up 52.9% in June
BioLineRx Ltd. (NASDAQ:BLRX - Get Free Report) was the recipient of a large increase in short interest in June. As of June 30th, there was short interest totalling 324,300 shares, an increase of 52.9% from the June 15th total of 212,100 shares. Based on an average daily volume of 374,900 shares, the short-interest ratio is presently 0.9 days.
BioLineRx Ltd. (NASDAQ:BLRX) Short Interest Update
BioLineRx Ltd. (NASDAQ:BLRX - Get Free Report) was the recipient of a significant increase in short interest in May. As of May 31st, there was short interest totalling 356,200 shares, an increase of 62.6% from the May 15th total of 219,100 shares. Based on an average daily trading volume, of 427,300 shares, the short-interest ratio is currently 0.8 days.
Short Interest in BioLineRx Ltd. (NASDAQ:BLRX) Decreases By 46.6%
BioLineRx Ltd. (NASDAQ:BLRX - Get Free Report) was the recipient of a large drop in short interest during the month of May. As of May 15th, there was short interest totalling 219,100 shares, a drop of 46.6% from the April 30th total of 410,600 shares. Based on an average daily volume of 410,600 shares, the days-to-cover ratio is currently 0.5 days.
BioLineRx (NASDAQ:BLRX) Releases Earnings Results
BioLineRx (NASDAQ:BLRX - Get Free Report) released its quarterly earnings results on Tuesday. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.28. The firm had revenue of $6.86 million for the quarter, compared to analyst estimates of $0.34 million. During the same period in the prior year, the business earned ($0.15) earnings per share.
BioLineRx (NASDAQ:BLRX) Given "Buy" Rating at HC Wainwright
HC Wainwright reiterated a "buy" rating and issued a $21.00 price objective on shares of BioLineRx in a research note on Wednesday.
Short Interest in BioLineRx Ltd. (NASDAQ:BLRX) Drops By 47.6%
BioLineRx Ltd. (NASDAQ:BLRX - Get Free Report) was the target of a significant decline in short interest in April. As of April 30th, there was short interest totalling 410,600 shares, a decline of 47.6% from the April 15th total of 783,600 shares. Based on an average daily volume of 416,500 shares, the days-to-cover ratio is currently 1.0 days.
BioLineRx (NASDAQ:BLRX) Rating Increased to Sell at StockNews.com
StockNews.com upgraded shares of BioLineRx to a "sell" rating in a research report on Friday.
FY2024 Earnings Forecast for BioLineRx Ltd. (NASDAQ:BLRX) Issued By HC Wainwright
BioLineRx Ltd. (NASDAQ:BLRX - Free Report) - Investment analysts at HC Wainwright cut their FY2024 earnings estimates for BioLineRx in a report issued on Tuesday, March 26th. HC Wainwright analyst J. Pantginis now expects that the biotechnology company will post earnings of ($1.03) per share for
Short Interest in BioLineRx Ltd. (NASDAQ:BLRX) Expands By 76.6%
BioLineRx Ltd. (NASDAQ:BLRX - Get Free Report) was the target of a significant increase in short interest in March. As of March 15th, there was short interest totalling 324,700 shares, an increase of 76.6% from the February 29th total of 183,900 shares. Based on an average daily trading volume, of 316,300 shares, the days-to-cover ratio is presently 1.0 days.
Research Analysts Issue Forecasts for BioLineRx Ltd.'s Q1 2024 Earnings (NASDAQ:BLRX)
BioLineRx Ltd. (NASDAQ:BLRX - Free Report) - Analysts at HC Wainwright issued their Q1 2024 earnings estimates for shares of BioLineRx in a research note issued to investors on Tuesday, March 26th. HC Wainwright analyst J. Pantginis forecasts that the biotechnology company will earn ($0.29) per s
BioLineRx (NASDAQ:BLRX) Upgraded to Sell at StockNews.com
StockNews.com upgraded shares of BioLineRx to a "sell" rating in a report on Wednesday.
BLRX: First Aphexda Sales Recognized
BioLineRx (NASDAQ:BLRX) Announces Earnings Results
BioLineRx (NASDAQ:BLRX - Get Free Report) issued its quarterly earnings results on Tuesday. The biotechnology company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.07. The business had revenue of $4.80 million for the quarter, compared to analyst estimates of $0.17 million. During the same quarter in the prior year, the firm earned ($0.09) EPS.
BioLineRx's (BLRX) "Buy" Rating Reiterated at HC Wainwright
HC Wainwright reiterated a "buy" rating and issued a $21.00 price target on shares of BioLineRx in a research note on Tuesday.
BioLineRx (BLRX) to Release Quarterly Earnings on Tuesday
BioLineRx (NASDAQ:BLRX) will be releasing earnings before the market opens on Tuesday, March 26, Zacks reports.
BioLineRx Ltd. (NASDAQ:BLRX) Sees Large Decrease in Short Interest
BioLineRx Ltd. (NASDAQ:BLRX - Get Free Report) was the target of a large decline in short interest during the month of February. As of February 29th, there was short interest totalling 183,900 shares, a decline of 8.1% from the February 14th total of 200,000 shares. Based on an average trading volume of 313,400 shares, the days-to-cover ratio is currently 0.6 days.
BLRX Mar 2024 1.000 call
BLRX: Poster Presentations
3 Top Penny Stocks for 5,000% Upside in 2024 and Beyond
BLRX May 2024 1.000 put
BioLineRx Ltd. (NASDAQ:BLRX) Sees Significant Drop in Short Interest
BioLineRx Ltd. (NASDAQ:BLRX - Get Free Report) saw a significant decrease in short interest during the month of December. As of December 15th, there was short interest totalling 114,800 shares, a decrease of 59.2% from the November 30th total of 281,100 shares. Based on an average daily trading volume, of 430,400 shares, the days-to-cover ratio is presently 0.3 days.
BioLineRx: Still A Buy, With Some Questions
Get BioLineRx News Delivered to You Automatically

Sign up to receive the latest news and ratings for BLRX and its competitors with MarketBeat's FREE daily newsletter.

You're missing out on these earnings plays (Ad)

FREE Guide: Unlock Earnings Season's Hidden Profits 15+ years of trading wisdom condensed into one powerful strategy. Learn to spot opportunities others miss during Q3 earnings. Daily intel included: Morning briefing, Midday update, Evening report. Claim your free Ultimate Strategy Guide To Trade Earnings Season now.

Limited time offer. Click here before this opportunity vanishes!

BLRX Media Mentions By Week

BLRX Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

BLRX
News Sentiment

1.18

0.93

Average
Medical
News Sentiment

BLRX News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

BLRX Articles
This Week

4

1

BLRX Articles
Average Week

Get BioLineRx News Delivered to You Automatically

Sign up to receive the latest news and ratings for BLRX and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:BLRX) was last updated on 7/17/2024 by MarketBeat.com Staff

From Our Partners